CTNNA1 Familial Expansion Study

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT05126290
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Collection of personal and family history from CAFÉ Study participants — OTHER
    Personal medical and genetic history, as well as relevant information about family history, will be collected from participants in the CAFÉ Study through an online data entry system

Study Details

The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.

Key Dates

Start date
Mar 16, 2021
Status verified
Feb 2026
Primary completion
Jan 1, 2028
Completion
Jan 1, 2028

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

Rate of cancer amongst carriers of CTNNA1 loss-of-function variants [ Time Frame: Through study completion, which will average 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Abramson Cancer Center of the University of PennsylvaniaPhiladelphiaPennsylvania19104
Bryson Katona, MD, PhD
[email protected]
215-349-8222
Bryson Katona, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By condition
Breast cancerGastric cancer
By specialty
OncologyBreast oncologyWomen's healthGI oncology
By research site
Abramson Cancer Center of the University of Pennsylvania· Philadelphia, PA

Related Studies